Nurlan Mammadzada

🚨 #ASCO25 DESTINY-Breast09 We’re witnessing a potential shift in the treatment landscape for HER2+ mBC. T-DXd + P showed a significant PFS benefit over THP as 1L tx. 🔹mPFS: 40.7 mo vs 26.9 mo 🔹HR: 0.56 (95% CI: 0.44–0.71), p < 0.00001 🔹44% ↓ risk of progression/death

🔥 #ASCO25: NIVOPOSTOP Adjuvant nivolumab + CRT significantly improved DFS in resected high-risk LA-HNSCC. 🧪 3-year DFS: 🔹NIVO+CRT: 63.1% 🔹CRT: 52.5% HR = 0.76 (95% CI: 0.60–0.98), p = 0.034

💥 ATOMIC trial: Adding atezolizumab to mFOLFOX6 significantly improved DFS in dMMR stage III colon cancer 📊 DFS: 86.4% vs 76.6% ⚖️ HR: 0.50 (95% CI: 0.34–0.72), p<0.0001 🧬 Benefit seen across key subgroups 🆕 New standard for dMMR stage III colon cancer #ASCO25 #CRC

📊 #PANOVA3: In locally advanced pancreatic cancer, TTFields + GnP outperformed GnP alone 👥 N=571 🔹 OS: 16.2 mo vs 14.2 mo (HR 0.82) 🔹 Median pain-free survival: 15.2 mo vs 9.1 mo (p=0.027) 🔹 PFS difference not statistically signif 🌍 Multicontinental, phase III trial #ASCO25

💡 Tumor Treating Fields (TTFields) use localized electric fields to disrupt cancer cell growth. 🧠 Proposed mechanisms: 🌀 Anti-mitotic 🧬 Impaired DNA repair 🧹 Autophagy modulation 🧫 Enhanced immunogenicity 🚷 Anti-migratory 💧 Altered cell permeability 📍 Approved for: GBM

💥 BREAKWATER (LBA3500) #ASCO25 1L EC + mFOLFOX6 in BRAF V600E mCRC: 🔹 PFS: 12.8 vs 7.1 mo 🔹 OS: 30.3 vs 16.1 mo (HR 0.53) 🔹 ORR: 66.7% vs 37.4% 🔹 DOR ≥26 mo: 19% ✅ Benefit across all subgroups #BRAF #mCRC #ColorectalCancer #ASCO25

🚨LumiNICE-203 @ #ASCO25 AlloNK + acimtamig in R/R HL: ✅ ORR: 88% ✅ CRR: 58% ➡ No ICANS, CRS in 25% (1 Gr3) 🧬 CD30-directed ADCC via bispecific acimtamig 🔬 PFS at 6mo: 61% 💥 Promising off-the-shelf NK cell therapy! #Lymphoma #HL #OncoTwitter #CellTherapy

At #ASCO25, Steven Wang shows that EOT ctDNA-MRD is a powerful prognostic marker in 1L DLBCL. 📌 2-yr PFS: MRD–: 90% vs MRD+: 23% 📌 2-yr OS: MRD–: 97% vs MRD+: 46% ➡️ Prog value independent of PET/CT and IPI ➡️ Integration into routine response assessment is strongly supported.

🔍 #ASCO25 FINER trial (CCTG MA.40) explores the AKT pathway in HR+/HER2– mBC post-CDK4/6i. 🧪 Ipatasertib + Fulvestrant vs Placebo: •PFS (ITT): 5.3 vs 1.9 mo (HR: 0.61; p=0.0007) •AKT-altered cohort: 5.4 vs 1.9 mo (HR: 0.47; p=0.0005) •ESR1 wt: 5.5 vs 2.0 mo (HR: 0.54)

🧩 Context on PI3K inhibition in PIK3CA-mut mBC: •SOLAR-1 (Alpelisib + Fulvestrant): → mPFS: 11.0 vs 5.7 months •BYLieve (Post-CDK4/6): → mPFS: 7.3 months 👀 INAVO120 shows the most mature and robust OS data yet for a PI3K inhibitor. #PIK3CA #Alpelisib #BreastCancer #mB

This is one of the most amazing papers ever. Future Nobel?? @NEJM drive.google.com/file/d/1Jfku5j…

🇦🇿🇦🇿🇦🇿🇦🇿

105 yrs ago, #Azerbaijan gave women equal voting rights, becoming one of the earliest nations to do so. Azerbaijan did it 1 year before US 9 yrs before UK 25 yrs before France 26 yrs before Italy 29 yrs before Belgium 52 yrs before Switzerland